AQR Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

AQR Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$517K	Buy	+84,020	New	+$599K	﹤0.01%	3104
2022 Q3	–	Sell	-42,932	Closed	-$1.69M	–	2302
2022 Q2	$1.69M	Buy	42,932 +24,384	+131%	+$723K	﹤0.01%	1181
2022 Q1	$684K	Buy	18,548 +834	+5%	+$52.2K	﹤0.01%	1697
2021 Q4	$1.73M	Buy	17,714 +4,569	+35%	+$492K	﹤0.01%	1260
2021 Q3	$1.64M	Buy	13,145 +1,792	+16%	+$216K	﹤0.01%	1267
2021 Q2	$1.42M	Sell	11,353 -2,521	-18%	-$300K	﹤0.01%	1411
2021 Q1	$1.88M	Buy	13,874 +286	+2%	+$35.5K	﹤0.01%	1236
2020 Q4	$1.24M	Buy	13,588 +3,600	+36%	+$312K	﹤0.01%	1405
2020 Q3	$743K	Buy	+9,988	New	+$765K	﹤0.01%	1563
2019 Q2	–	Sell	-7,092	Closed	-$504K	–	2167
2019 Q1	$504K	Buy	+7,092	New	+$449K	﹤0.01%	1805

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's RNAC Position: Q1 2026 in Review

AQR Capital Management opened a new position in Cartesian Therapeutics (RNAC) in Q1 2026: 84,020 shares worth $517K. The stake represents ﹤0.01% of the portfolio and ranks #3104 among its holdings. This is a return to the name: AQR Capital Management previously reported a position in RNAC as recently as Q2 2022.

AQR Capital Management first reported a position in RNAC in Q1 2019 and has held it in 10 quarters since. The position peaked at $1.88M in Q1 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

AQR Capital Management held 84,020 shares of Cartesian Therapeutics worth $517K as of Q1 2026.
Cartesian Therapeutics was a new AQR Capital Management position in Q1 2026.
Cartesian Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3104 holding.
AQR Capital Management first reported a position in Cartesian Therapeutics in Q1 2019 and has held it in 10 quarters since.
AQR Capital Management's Cartesian Therapeutics position peaked at $1.88M in Q1 2021.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.